:: دوره 3، شماره 4 - ( 6-1393 ) ::
برگشت به فهرست نسخه ها
Hepatitis C Virus and Vaccine Development
:   (10439 مشاهده)
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical use. DNA vaccines have some advantages such as producing feasibility and generating intensive cellular and humoral immune responses. Activation and improvement of natural immune defense mechanisms is a necessity for the development of an effective HCV vaccine. This article discusses the current status of therapies for hepatitis C, the promising new therapies and the experimental strategies to develop an HCV vaccine.
متن کامل [PDF 183 kb]   (3444 دریافت)    
نوع مطالعه: Original Article | موضوع مقاله: Infectious disease (Molecular and Cellular aspects)
دریافت: 1393/3/2 | پذیرش: 1393/5/11 | انتشار: 1393/6/19


XML   English Abstract   Print



بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.
دوره 3، شماره 4 - ( 6-1393 ) برگشت به فهرست نسخه ها